In acute treatment , the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale ( ABC-I ) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group .
According to the discontinuation phase , the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group .
The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments .
Conclusion In relation to the current systematic review , risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD .
Although its acceptability is comparable to placebo , treatment with risperidone is well tolerated in children and adolescents with ASD
Background Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder ( ASD ) in children and adolescents .
Objective The aim of this systematic review was to determine the efficacy , acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD .
Cognitive effects of risperidone in children with autism and irritable behavior.
OBJECTIVE The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior . METHOD Thirty-eight children , ages 5 - 17 years with autism and severe behavioral disturbance , were r and omly assigned to risperidone ( 0.5 to 3.5 mg/day ) or placebo for 8 weeks . This sample of 38 was a subset of 101 subjects who participated in the clinical trial ; 63 were unable to perform the cognitive tasks . A double-blind placebo-controlled parallel groups design was used . Dependent measures included tests of sustained attention , verbal learning , h and -eye coordination , and spatial memory assessed before , during , and after the 8-week treatment . Changes in performance were compared by repeated measures ANOVA . RESULTS Twenty-nine boys and 9 girls with autism and severe behavioral disturbance and a mental age > or=18 months completed the cognitive part of the study . No decline in performance occurred with risperidone . Performance on a cancellation task ( number of correct detections ) and a verbal learning task ( word recognition ) was better on risperidone than on placebo ( without correction for multiplicity ) . Equivocal improvement also occurred on a spatial memory task . There were no significant differences between treatment conditions on the Purdue Pegboard ( h and -eye coordination ) task or the Analog Classroom Task ( timed math test ) . CONCLUSION Risperidone given to children with autism at doses up to 3.5 mg for up to 8 weeks appears to have no detrimental effect on cognitive performance
In acute treatment , the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale ( ABC-I ) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group .
According to the discontinuation phase , the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group .
The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments .
Conclusion In relation to the current systematic review , risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD .
Although its acceptability is comparable to placebo , treatment with risperidone is well tolerated in children and adolescents with ASD
Background Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder ( ASD ) in children and adolescents .
Objective The aim of this systematic review was to determine the efficacy , acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD .